Alexza Announces Adasuve(TM) (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012 - MarketWatch
Links shared publicly online about this topic.
- 61total visits
Alexza Announces Adasuve(TM) (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012 - MarketWatch
View full resource at marketwatch.com
Tags: Schizophrenia, Psychotic Disorder
Most Recently Shared on August 20, 2011 at 12:31 pm By:
Dr Stephen Ayer - Schizophrenia Society of Nova Scotia
Alexza Announces Adasuve(TM) (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012 - http://t.co/2gqMdwN #schizophrenia
Also Shared By:
FDA Issues Complete Response Letter to NDA for Adasuve - MPR
empr.com — “Alexza Pharmaceuticals announced that it has received a complete response letter from the FDA regarding its New Drug Application (NDA) for Adasuve (Staccato loxapine) inhalation powder, 5mg and 10mg, for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.” View full resource at empr.com
Most Recently Shared on May 7, 2012 at 3:35 pm By:
FDA Issues Complete Response Letter to NDA for #Adasuve #Alexza #loxapine #inhalation #agitation http://t.co/UloQRAV8
Alexza Announces Adasuve Staccato (Loxapine) PDUFA Goal Date of February 4, 2012
drugs.com — “Adasuve (loxapine) is a new drug in development for the treatment of agitation in adults with schizophrenia or bipolar disorder. Adasuve information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on August 25, 2011 at 1:18 am By:
Drugs and Devices OW OW Health
Alexza Announces Adasuve Staccato (Loxapine) PDUFA Goal Date of February 4, 2012: MOUNTAIN VIEW, Calif., A... http://t.co/aym2Xh8 #drug
NDA Accepted for Adasuve for Agitation in Schizophrenia - MPR
empr.com — “Alexza Pharmaceuticals announced that the FDA has accepted its new drug application (NDA) for Adasuve (Staccato loxapine) for the rapid treatment of agitation in adults with schizophrenia.” View full resource at empr.com
Most Recently Shared on August 19, 2011 at 4:02 pm By:
NDA Accepted for Adasuve for Agitation in Schizophrenia http://ow.ly/67DhH #schizophrenia
Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA
drugs.com — “AZ-004 (Staccato loxapine) is a new drug in development for the treatment of agitation in patients with schizophrenia or bipolar disorder. AZ-004 information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on August 6, 2011 at 1:15 am By:
Drugs and Devices OW OW Health
Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA: MOUNTAIN VIEW, Calif., Aug. 5, 2011 /PRNe... http://bit.ly/oqeC1F #drug
Alexza Pharmaceuticals — Investor Relations - RSS Content
phx.corporate-ir.net — “Alexza Pharmaceuticals Welcome” View full resource at phx.corporate-ir.net
Most Recently Shared on August 5, 2011 at 1:15 pm By:
eyeonfda Pharma and Health Lawyer
Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA 4 #Schizophrenia or #Bipolar Disorder - http://ow.ly/5VZLR #FDA
Alexza's Staccato® Nicotine Licensed To Cypress Bioscience
medicalnewstoday.com — “Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. (Nasdaq: CYPB). The Staccato nicotine technology is a nove” View full resource at medicalnewstoday.com
Most Recently Shared on August 28, 2010 at 2:00 pm By:
Alexza's Staccato® Nicotine Licensed To Cypress Bioscience http://mnt.to/3J24 #smoking #quitsmoking
Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA
medicalnewstoday.com — “Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA). AZ-004” View full resource at medicalnewstoday.com
Most Recently Shared on December 16, 2009 at 11:17 am By:
MNT Clinical Trials Health News
Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA http://mnt.to/3vxf
Advertisement
Peter H Brown
@PeterBrownPsy
Alexza Announces Adasuve(TM) (Staccato® Loxapine) PDUFA Goal Date of February ... http://t.co/3ssUlkU #bipolar
1 year ago...